October 28, 2019
FDA extends the use of Lilleta
FDA has expanded the duration of use of Allergan’s Lilleta to prevent pregnancy for up to six years, after Supplemental…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
October 28, 2019
Actinium trial testing Iomab-B in AML patients still highly encouraging
Actinium Pharmaceuticals on Monday announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B at 50% of total of 150-patient, compared to physician’s choice of salvage chemotherapy in patients age 55 and above with active, relapsed or refractory AML (Acute Myeloid Leukemia).
October 28, 2019
Biohaven enrolls 880 patients testing troriluzole in generalized anxiety disorder
Biohaven Pharmaceutical has enrolled over 880 patients in less than nine months, in its pivotal Phase 3 clinical trial of troriluzole in generalized anxiety disorder (GAD).
October 28, 2019
Salix Pharmaceuticals presents certain constipation treatment Trulance in San Antonio
Bausch Health Companies’s gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the…
October 25, 2019
Alvogen sells Central and Eastern European business to Zentiva
Alvogen is selling its Central and Eastern European business to Zentiva, for an undisclosed amount, to focus on developing other areas, with the transaction to be closed in first quarter of 2020.
October 25, 2019
Vistin Pharma ends Q3 2019 with revenue up 31%, and goes to net gain vs loss in Q3 2018
Vistin Pharma posted net financial gain for the third quarter NOK 68.1 million (€6.68M), compared to a net loss of NOK 4.3 million in the same period last year, resulting with the net financial gain for the quarter primarily relates to an unrealised gain on oil derivatives of NOK 66.7 million.
October 25, 2019
Neopharma, Elevar Therapeutics form JV to sell anticancer drug Rivoceranib
Abu Dhabi-based pharmaceutical manufacturer Neopharma and US-based Elevar Therapeutics formed a 50-50 joint venture in UAE, to organize selling Rivoceranib, a targeted anticancer drug and conduct clinical trials for other pipeline candidates.
October 24, 2019
Allergan gets additional Botox approval from FDA
Allergan said Thursday that the U.S. FDA approved its supplemental Biologics License Application (sBLA) for Botox for the treatment younger patients with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP).
October 23, 2019
Hemogenyx Pharmaceuticals in deal to develop humanized mice with a global pharma company
Hemogenyx Pharmaceuticals has signed a research agreement through is subsidiary Immugenyx, to develop humanized mice as a tool for drug development and testing, including with a global pharmaceutical company, whose identity must remain hidden at its request.
October 22, 2019
Novartis increses net sales. Net income $2B
Novartis has ended third quarter 2019 with reported net income of $2.0 billion, which as an 8% increase, driven by higher operating income and higher income from associated companies, saying in the press release Tuesday that its EPS was USD 0.90 (+11%, +14% cc), growing faster than net income driven by lower weighted average number of shares outstanding.